Equities analysts expect PetIQ Inc (NASDAQ:PETQ) to announce earnings per share (EPS) of $0.25 for the current fiscal quarter, according to Zacks. Five analysts have made estimates for PetIQ’s earnings, with the lowest EPS estimate coming in at $0.23 and the highest estimate coming in at $0.28. PetIQ reported earnings of $0.29 per share in the same quarter last year, which would indicate a negative year-over-year growth rate of 13.8%. The firm is scheduled to issue its next earnings report after the market closes on Tuesday, November 13th.
According to Zacks, analysts expect that PetIQ will report full-year earnings of $0.82 per share for the current financial year, with EPS estimates ranging from $0.80 to $0.85. For the next year, analysts expect that the business will post earnings of $0.93 per share, with EPS estimates ranging from $0.87 to $1.00. Zacks Investment Research’s EPS calculations are a mean average based on a survey of research analysts that cover PetIQ.
PetIQ (NASDAQ:PETQ) last announced its earnings results on Tuesday, August 14th. The company reported $0.41 EPS for the quarter, topping the consensus estimate of $0.39 by $0.02. The business had revenue of $171.10 million for the quarter, compared to the consensus estimate of $148.48 million. PetIQ had a positive return on equity of 11.40% and a negative net margin of 0.76%. PetIQ’s revenue was up 96.2% compared to the same quarter last year.
In related news, major shareholder Ecp Helios Partners Iv, L.P. sold 1,838,836 shares of the company’s stock in a transaction on Monday, October 1st. The shares were sold at an average price of $37.15, for a total value of $68,312,757.40. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, insider Will Santana sold 713,167 shares of the company’s stock in a transaction on Monday, October 1st. The shares were sold at an average price of $37.15, for a total transaction of $26,494,154.05. The disclosure for this sale can be found here. In the last three months, insiders sold 3,044,477 shares of company stock worth $113,302,180. 45.26% of the stock is currently owned by company insiders.
Several institutional investors and hedge funds have recently added to or reduced their stakes in PETQ. Eos Management L.P. increased its holdings in PetIQ by 2,470.1% during the 3rd quarter. Eos Management L.P. now owns 136,511,326 shares of the company’s stock worth $3,473,000 after purchasing an additional 131,199,803 shares in the last quarter. Wasatch Advisors Inc. increased its holdings in PetIQ by 452.1% during the 2nd quarter. Wasatch Advisors Inc. now owns 1,944,321 shares of the company’s stock worth $52,224,000 after purchasing an additional 1,592,157 shares in the last quarter. State of New Jersey Common Pension Fund D increased its holdings in PetIQ by 6.4% during the 3rd quarter. State of New Jersey Common Pension Fund D now owns 1,000,000 shares of the company’s stock worth $39,310,000 after purchasing an additional 60,000 shares in the last quarter. BlackRock Inc. increased its holdings in PetIQ by 5.5% during the 2nd quarter. BlackRock Inc. now owns 835,035 shares of the company’s stock worth $22,427,000 after purchasing an additional 43,693 shares in the last quarter. Finally, Pembroke Management LTD acquired a new position in shares of PetIQ during the 2nd quarter worth about $18,637,000. Institutional investors and hedge funds own 74.33% of the company’s stock.
Shares of PETQ traded down $0.24 on Friday, hitting $33.90. The company’s stock had a trading volume of 1,911 shares, compared to its average volume of 436,217. The company has a market capitalization of $820.54 million, a P/E ratio of 87.13, a PEG ratio of 1.68 and a beta of 1.58. The company has a debt-to-equity ratio of 0.56, a current ratio of 2.00 and a quick ratio of 0.90. PetIQ has a fifty-two week low of $17.03 and a fifty-two week high of $43.93.
PetIQ, Inc operates as a pet health and wellness company. It provides veterinarian services and veterinarian-grade pet products, including prescription (Rx) medications, over-the-counter (OTC) flea and tick preventatives, and health and wellness products for dogs and cats. The company offers pet prescription medications, including products for arthritis, thyroid, and diabetes and pain treatments, as well as heartworm preventatives, antibiotics, and other specialty medications; over-the-counter medications and supplies, such as flea and tick control products in various forms comprising spot on treatments, chewables, and collars; and health and wellness products consisting of specialty treats and other pet products, which include dental treats and nutritional supplements.
Featured Article: How to Invest in the Dividend Aristocrat Index
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for PetIQ Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PetIQ and related companies with MarketBeat.com's FREE daily email newsletter.